Special Issue "New Advances on Zika Virus Research"
Deadline for manuscript submissions: closed (30 September 2018)
Dr. Luis Martinez-Sobrido
Department of Microbiology and Immunology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 672, Rochester, NY 14642, USA
Website | E-Mail
Fax: +1 585 473 9573
Interests: virology; vaccines; antivirals; influenza viruses; arenaviruses; Zika virus; innate immunity; adaptive immunity; virus–host interaction
Zika virus (ZIKV) is a mosquito-borne member of the Flaviviridae family that has been known to cause sporadic outbreaks in Africa and Southeast Asia. Recently, ZIKV has been associated with Guillain-Barre syndrome and microcephaly in the infants of infected mothers, a condition where infants are born with abnormally-small heads. The explosion of recent pandemics of ZIKV throughout South and Central America, the South Pacific and the Caribbean, and the potential threat to the United States, represent the most recent unexpected arrival of an arthropod-borne viral disease in the Western Hemisphere over the past 20 years. To date, there are no Food and Drug Administration (FDA)-licensed prophylactics (vaccines) or therapeutics (antivirals) available for the treatment of ZIKV disease in humans, which has the potential to affect millions of people worldwide. The significance of ZIKV in human health, together with the limited existing armamentarium to combat ZIKV infection, highlight the importance of developing effective countermeasures to prevent or treat ZIKV infection in humans. In this Special Issue, we will focus on the most recent discoveries in ZIKV research, including the molecular biology of the virus, virus–host interactions, antivirals, and vaccine development.Dr. Luis Martinez-Sobrido
Dr. Fernando Almazan Toral
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Zika virus (ZIKV)
- Guillain-Barre syndrome
- ZIKV vaccines
- ZIKV antivirals
- molecular biology ZIKV
- reverse genetics ZIKV
- ZIKV-host interactions